“Easing of FDI in the pharmaceutical sector will be a game changer, as this move would catapult India as a prime investment destination, especially keeping in view the numerous inherent strengths associated with this sector. While India prepares itself to become a hub for pharma sector, this progressive step for further liberalisation will help Pharmaceutical companies in India to make, develop and innovate new medicines for the world“ said Dr Rajive Modi, Chairman, CII Pharmaceutical Committee, Chairman & Mg Director, Cadila Pharmaceuticals Ltd, in a statement.